{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:30:25Z","timestamp":1781649025122,"version":"3.54.5"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Tetraphase Pharmaceuticals, Inc."},{"DOI":"10.13039\/501100000777","name":"University of Leeds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Eravacycline is a novel synthetic fluorocycline antibacterial approved for complicated intra-abdominal infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The purpose of this study was to assess the in vitro activities of eravacycline and comparator antibiotics against contemporary clinical isolates of Clostridioides difficile representing common ribotypes, including isolates with decreased susceptibility to metronidazole and vancomycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinical C. difficile strains from six common or emerging ribotypes were used to test the in vitro activities of eravacycline and comparator antibiotics (fidaxomicin, vancomycin and metronidazole) by broth microdilution. In addition, MBC experiments, time\u2013kill kinetic studies and WGS experiments were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 234 isolates were tested, including ribotypes RT001 (n\u2009=\u200937), RT002 (n\u2009=\u200941), RT014-020 (n\u2009=\u200939), RT027 (n\u2009=\u200942), RT106 (n\u2009=\u200938) and RT255 (n\u2009=\u200937). MIC50\/90 values were lowest for eravacycline (\u22640.0078\/0.016\u2009mg\/L), followed by fidaxomicin (0.016\/0.063\u2009mg\/L), metronidazole (0.25\/1.0\u2009mg\/L) and vancomycin (2.0\/4.0\u2009mg\/L). MBCs were lower for eravacycline compared with vancomycin for all ribotypes tested. Both vancomycin and eravacycline demonstrated bactericidal killing, including for epidemic RT027. The presence of the tetM or tetW resistance genes did not affect the MIC of eravacycline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study demonstrated potent in vitro activity of eravacycline against a large collection of clinical C. difficile strains that was not affected by ribotype, susceptibility to vancomycin or the presence of certain tet resistance genes. Further development of eravacycline as an antibiotic to be used in patients with Clostridioides difficile infection is warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa289","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T19:10:09Z","timestamp":1592334609000},"page":"2879-2884","source":"Crossref","is-referenced-by-count":17,"title":["In vitro activity of eravacycline against common ribotypes of Clostridioides difficile"],"prefix":"10.1093","volume":"75","author":[{"given":"Eug\u00e9nie","family":"Bass\u00e8res","sequence":"first","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurshida","family":"Begum","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Lancaster","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J","family":"Gonzales-Luna","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-3030","authenticated-orcid":false,"given":"Travis J","family":"Carlson","sequence":"additional","affiliation":[{"name":"Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Miranda","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnuva","family":"Rashid","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Jahangir","family":"Alam","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Eyre","sequence":"additional","affiliation":[{"name":"Big Data Institute, University of Oxford, Oxford, UK"},{"name":"National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H","family":"Wilcox","sequence":"additional","affiliation":[{"name":"Healthcare Associated Infections Research Group, Leeds Institute for Medical Research, University of Leeds, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, UK"},{"name":"Microbiology, Leeds Teaching Hospitals NHS Trust, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2063-7503","authenticated-orcid":false,"given":"Kevin W","family":"Garey","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"2020101416053334400_dkaa289-B1","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"key":"2020101416053334400_dkaa289-B2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"key":"2020101416053334400_dkaa289-B3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020101416053334400_dkaa289-B4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020101416053334400_dkaa289-B5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a Phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101416053334400_dkaa289-B6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"2020101416053334400_dkaa289-B7","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1128\/AAC.04296-14","article-title":"Effects of tigecycline and vancomycin administration on established Clostridium difficile infection","volume":"59","author":"Theriot","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416053334400_dkaa289-B8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jac\/dkl364","article-title":"Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model","volume":"58","author":"Baines","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2020101416053334400_dkaa289-B9","doi-asserted-by":"crossref","first-page":"e02206","DOI":"10.1128\/AAC.02206-17","article-title":"Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates","volume":"62","author":"Snydman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416053334400_dkaa289-B10","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416053334400_dkaa289-B11","doi-asserted-by":"crossref","first-page":"ofz552","DOI":"10.1093\/ofid\/ofz552","article-title":"Eosinopenia and binary toxin increase mortality in hospitalized patients with Clostridioides difficile infection","volume":"7","author":"Carlson","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2020101416053334400_dkaa289-B12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/JCM.03591-14","article-title":"Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology","volume":"53","author":"Martinson","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2020101416053334400_dkaa289-B13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.anaerobe.2014.03.002","article-title":"Investigation of potentially pathogenic Clostridium difficile contamination in household environs","volume":"27","author":"Alam","year":"2014","journal-title":"Anaerobe"},{"key":"2020101416053334400_dkaa289-B14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/22221751.2020.1721335","article-title":"PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255","volume":"9","author":"Gonzales-Luna","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2020101416053334400_dkaa289-B15","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.diagmicrobio.2011.04.012","article-title":"Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficile","volume":"70","author":"Citron","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020101416053334400_dkaa289-B16","year":"2014"},{"key":"2020101416053334400_dkaa289-B17","doi-asserted-by":"crossref","first-page":"ofz013","DOI":"10.1093\/ofid\/ofz013","article-title":"Epidemic Clostridioides difficile ribotype 027 lineages: comparisons of Texas versus worldwide strains","volume":"6","author":"Endres","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020101416053334400_dkaa289-B18","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1216064","article-title":"Diverse sources of C. difficile infection identified on whole-genome sequencing","volume":"369","author":"Eyre","year":"2013","journal-title":"N Engl J Med"},{"key":"2020101416053334400_dkaa289-B19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/10635150390235520","article-title":"A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood","volume":"52","author":"Guindon","year":"2003","journal-title":"Syst Biol"},{"key":"2020101416053334400_dkaa289-B20","doi-asserted-by":"crossref","first-page":"e1004041","DOI":"10.1371\/journal.pcbi.1004041","article-title":"ClonalFrameML: efficient inference of recombination in whole bacterial genomes","volume":"11","author":"Didelot","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"2020101416053334400_dkaa289-B21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1101\/gr.074492.107","article-title":"Velvet: algorithms for de novo short read assembly using de Bruijn graphs","volume":"18","author":"Zerbino","year":"2008","journal-title":"Genome Res"},{"key":"2020101416053334400_dkaa289-B22","doi-asserted-by":"crossref","first-page":"e02790","DOI":"10.1128\/mBio.02790-18","article-title":"A role for tetracycline selection in recent evolution of agriculture-associated Clostridium difficile PCR ribotype 078","volume":"10","author":"Dingle","year":"2019","journal-title":"mBio"},{"key":"2020101416053334400_dkaa289-B23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmi.2017.07.012","article-title":"Susceptibilities of clinical Clostridium difficile isolates to antimicrobials: a systematic review and meta-analysis of studies since 1970","volume":"24","author":"Khanafer","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2020101416053334400_dkaa289-B24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-019-00767-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of eravacycline","volume":"58","author":"McCarthy","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2020101416053334400_dkaa289-B25","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","article-title":"Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic","volume":"56","author":"Grossman","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/2879\/33885551\/dkaa289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/2879\/33885551\/dkaa289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T20:07:48Z","timestamp":1602706068000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/10\/2879\/5877003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,7,28]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa289","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,7,28]]}}}